ADVERTISEMENT

Novel treatments under study for chronic graft-versus-host disease in allo-HCT

Randy Dotinga   |   Conference Report   |   27 October 2020
ADVERTISEMENT

FROM ALF 2020

Physicians are gaining a greater understanding of the pathophysiology of chronic graft-versus-host disease (cGVHD) in allo-hematopoietic cell transplantation (allo-HCT), a hematologist/oncologist told colleagues, and novel treatments are being tested.

However, options remain limited. There’s only one Food and Drug Administration–approved therapy for cGVHD that’s failed one or...

          

Topic Challenges

left
right